Cargando…
Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial
BACKGROUND: The Basel Asymptomatic High-Risk Diabetics’ Outcome Trial (BARDOT) demonstrated that asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) were at increased risk of major adverse cardiovascular events (MACEs) at 2-year follow-up. It remains unclear wheth...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440314/ https://www.ncbi.nlm.nih.gov/pubmed/33884468 http://dx.doi.org/10.1007/s00259-021-05349-5 |
_version_ | 1783752684914868224 |
---|---|
author | Caobelli, Federico Haaf, Philip Haenny, Gianluca Pfisterer, Matthias Zellweger, Michael J. |
author_facet | Caobelli, Federico Haaf, Philip Haenny, Gianluca Pfisterer, Matthias Zellweger, Michael J. |
author_sort | Caobelli, Federico |
collection | PubMed |
description | BACKGROUND: The Basel Asymptomatic High-Risk Diabetics’ Outcome Trial (BARDOT) demonstrated that asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) were at increased risk of major adverse cardiovascular events (MACEs) at 2-year follow-up. It remains unclear whether this finding holds true even for a longer follow-up. METHODS: Four hundred patients with type 2 diabetes, neither history nor symptoms of coronary artery disease (CAD), were evaluated clinically and with MPS. Patients were followed up for 5 years. Major adverse cardiovascular events (MACEs) were defined as all-cause death, myocardial infarction, or late coronary revascularization. RESULTS: At baseline, an abnormal MPS (SSS ≥ 4 or SDS ≥ 2) was found in 87 of 400 patients (22%). MACE within 5 years occurred in 14 patients with abnormal MPS (16.1%) and in 22 with normal scan (1.7%), p = 0.009; 15 deaths were recorded. Patients with completely normal MPS (SSS and SDS = 0) had lower rates of MACEs than patients with abnormal scans (2.5% vs. 7.0%, p = 0.032). Patients with abnormal MPS who had undergone revascularization had a lower mortality rate and a better event-free survival from MI and revascularization than patients with abnormal MPS who had either undergone medical therapy only or could not be revascularized (p = 0.002). CONCLUSIONS: MPS may have prognostic value in asymptomatic diabetic patients at high cardiovascular risk over a follow-up period of 5 years. Patients with completely normal MPS have a low event rate and may not need retesting within 5 years. Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05349-5. |
format | Online Article Text |
id | pubmed-8440314 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-84403142021-10-01 Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial Caobelli, Federico Haaf, Philip Haenny, Gianluca Pfisterer, Matthias Zellweger, Michael J. Eur J Nucl Med Mol Imaging Original Article BACKGROUND: The Basel Asymptomatic High-Risk Diabetics’ Outcome Trial (BARDOT) demonstrated that asymptomatic diabetic patients with an abnormal myocardial perfusion scintigraphy (MPS) were at increased risk of major adverse cardiovascular events (MACEs) at 2-year follow-up. It remains unclear whether this finding holds true even for a longer follow-up. METHODS: Four hundred patients with type 2 diabetes, neither history nor symptoms of coronary artery disease (CAD), were evaluated clinically and with MPS. Patients were followed up for 5 years. Major adverse cardiovascular events (MACEs) were defined as all-cause death, myocardial infarction, or late coronary revascularization. RESULTS: At baseline, an abnormal MPS (SSS ≥ 4 or SDS ≥ 2) was found in 87 of 400 patients (22%). MACE within 5 years occurred in 14 patients with abnormal MPS (16.1%) and in 22 with normal scan (1.7%), p = 0.009; 15 deaths were recorded. Patients with completely normal MPS (SSS and SDS = 0) had lower rates of MACEs than patients with abnormal scans (2.5% vs. 7.0%, p = 0.032). Patients with abnormal MPS who had undergone revascularization had a lower mortality rate and a better event-free survival from MI and revascularization than patients with abnormal MPS who had either undergone medical therapy only or could not be revascularized (p = 0.002). CONCLUSIONS: MPS may have prognostic value in asymptomatic diabetic patients at high cardiovascular risk over a follow-up period of 5 years. Patients with completely normal MPS have a low event rate and may not need retesting within 5 years. Patients with an abnormal MPS have higher event rates and may benefit from a combined medical and revascularization approach. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-021-05349-5. Springer Berlin Heidelberg 2021-04-21 2021 /pmc/articles/PMC8440314/ /pubmed/33884468 http://dx.doi.org/10.1007/s00259-021-05349-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Caobelli, Federico Haaf, Philip Haenny, Gianluca Pfisterer, Matthias Zellweger, Michael J. Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial |
title | Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial |
title_full | Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial |
title_fullStr | Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial |
title_full_unstemmed | Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial |
title_short | Prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter BARDOT trial |
title_sort | prognostic value of myocardial perfusion scintigraphy in asymptomatic patients with diabetes mellitus at high cardiovascular risk: 5-year follow-up of the prospective multicenter bardot trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440314/ https://www.ncbi.nlm.nih.gov/pubmed/33884468 http://dx.doi.org/10.1007/s00259-021-05349-5 |
work_keys_str_mv | AT caobellifederico prognosticvalueofmyocardialperfusionscintigraphyinasymptomaticpatientswithdiabetesmellitusathighcardiovascularrisk5yearfollowupoftheprospectivemulticenterbardottrial AT haafphilip prognosticvalueofmyocardialperfusionscintigraphyinasymptomaticpatientswithdiabetesmellitusathighcardiovascularrisk5yearfollowupoftheprospectivemulticenterbardottrial AT haennygianluca prognosticvalueofmyocardialperfusionscintigraphyinasymptomaticpatientswithdiabetesmellitusathighcardiovascularrisk5yearfollowupoftheprospectivemulticenterbardottrial AT pfisterermatthias prognosticvalueofmyocardialperfusionscintigraphyinasymptomaticpatientswithdiabetesmellitusathighcardiovascularrisk5yearfollowupoftheprospectivemulticenterbardottrial AT zellwegermichaelj prognosticvalueofmyocardialperfusionscintigraphyinasymptomaticpatientswithdiabetesmellitusathighcardiovascularrisk5yearfollowupoftheprospectivemulticenterbardottrial AT prognosticvalueofmyocardialperfusionscintigraphyinasymptomaticpatientswithdiabetesmellitusathighcardiovascularrisk5yearfollowupoftheprospectivemulticenterbardottrial |